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Abstract
CLL remains incurable with chemoimmunotherapy, and allogeneic hematopoietic stem cell
transplantation (HSCT) offers potential for cure. We assessed the outcomes of 108 CLL patients
undergoing first allogeneic HSCTs, 76 with reduced intensity (RIC) and 32 with myeloablative
(MAC) conditioning between 1998 and 2009 at Dana-Farber Cancer Institute. With median
follow-up 5.9 years in surviving patients, the 5 year OS for the entire cohort is 63% for RIC
regimens and 49% for MAC regimens (p=0.18). The risk of death declined significantly starting in
2004 and we found that 5 year OS for HSCT between 2004–2009 was 83% for RIC regimens
compared to 47% for MAC regimens (p=0.003). For RIC transplantation, we developed a
prognostic model based on predictors of PFS, specifically remission status, LDH, comorbidity
score and lymphocyte count, and found 5-year PFS 83% for score 0, 63% for score 1, 24% for
score 2, and 6% for score >= 3 (p<0.0001). We conclude that RIC HSCT for CLL in the current
era is associated with excellent long-term PFS and OS, and, as potentially curative therapy, should
be considered early in the disease course of relapsed high-risk CLL patients.
Keywords
CLL; RIC; myeloablative; SCT; prognostic model
Correspondence should be addressed to Jennifer R Brown, MD, PhD, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston,
MA 02215; telephone 617-632-4564; fax 617-582-7909; jbrown2@partners.org.
*JRB and HTK contributed equally to this work.
Presented in part at the Annual Meeting of ASH, December 2008
AUTHORSHIP CONTRIBUTIONS
JRB, HTK, JHA and EPA designed the research. JRB, HTK, PA, CC, DCF, VH, JK, JR, CW, JHA, RJS, JGG and EPA performed the
research. PA, CC, DCF, VH, JK, JR, JHA, RJS, JGG and EPA enrolled patients. JRB and HTK analyzed the data. JRB and HTK
wrote the paper with input from PA, JHA, RJS, JGG and EPA.
The authors have no conflicts of interest to disclose.
NIH Public Access
Author Manuscript
Leukemia. Author manuscript; available in PMC 2013 August 01.
Published in final edited form as:
Leukemia. 2013 February ; 27(2): 362–369. doi:10.1038/leu.2012.228.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
INTRODUCTION
Despite recent therapeutic advances that include highly effective chemoimmunotherapy
(CIT) regimens(1–3) and alemtuzumab(4), chronic lymphocytic leukemia (CLL) remains an
incurable disease with standard therapy, with reported overall survival after third-line
chemotherapy ranging from 34–47 months(5, 6). Although autologous transplantation
(ASCT) initially appeared promising, long-term follow-up of CLL patients treated with
ASCT has revealed that relapse is ongoing, suggesting that ASCT is unlikely to be
curative(7–9). Furthermore, recent randomized trials of autologous SCT have shown
improved EFS without impact on OS(10, 11), and the EFS observed with ASCT in these
studies is similar to that seen with FCR CIT(12, 13).
Early studies of myeloablative allogeneic transplantation (MAC) established that long-term
remissions are possible(14–16), albeit with a high NRM, ranging from 10% to 40% even in
relatively young patients(8, 15–21). Interest therefore turned toward RIC approaches in an
effort to reduce NRM(22–25), which is now generally in the 15–30% range at 3–5 year
follow-up(24–27). Recent data also suggest that RIC HSCT can induce long-term disease
free survival even in very high-risk CLL with deletion 17p(24, 26).
However, particularly for patients with refractory or bulky disease at transplant, relapse
remains a significant problem, with cumulative incidence as high as 36–40% at 4–5 year
follow-up(24–27), and in our own DFCI series of refractory patients, 48% at two years(28).
Since outcomes of transplantation have improved over the last decade, we were interested in
reassessing the outcomes of these patients, and in particular looking at whether dose
intensity in CLL patients eligible for myeloablative HSCT might have benefit in a more
modern era. A retrospective comparison of RIC HSCT patients to matched patients who
received MAC found that, as expected, NRM was reduced in the RIC HSCT patients, but
this benefit was offset by an increased relapse rate, leading to equivalent event-free and
overall survival(29). We have evaluated the outcomes of all CLL patients who underwent
HSCT at DFCI from 1998 to 2009. Although over this period the patients who had RIC
HSCT differed systematically from those who underwent MAC HSCT, we found that since
2004, the patient groups were well-matched and patients undergoing RIC HSCT benefited
from reduced NRM and reduced relapse, leading to significantly better overall survival not
seen with MAC HSCT. Furthermore, we developed a prognostic model for outcome which
correlates well with PFS, OS and relapse in our cohort. The improved outcomes of RIC
HSCT and the utility of our prognostic model for patient selection further support the earlier
consideration of HSCT in these patients.
PATIENTS AND METHODS
Patient Population
One hundred and eight consecutive patients with a diagnosis of CLL who underwent first
allogeneic HSCT from a HLA-matched adult donor (6/6) from 1998 to 2009 at DFCI were
included in the initial analysis. The RIC-specific analysis then focused on 76 patients who
underwent allogeneic HSCT between January 2001 and December 2009. Eligibility criteria
for allogeneic HSCT for CLL typically included disease refractory to purine analogues or
similar intensity therapy, disease showing progressively less benefit from purine analogues
as demonstrated by a remission duration less than 12–24 months, failure to respond to
salvage therapy, or the presence of 17p deletion. Patients were treated prospectively on
treatment plans or research protocols that were approved by the Dana-Farber/Harvard
Cancer Center Institutional Review Board, and informed consent was obtained from all
patients prior to therapy. Transplantation eligibility requirements included ECOG
performance status 0–2, left ventricular ejection fraction >30%, and no uncontrolled
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infection. The choice of RIC or MAC was at the discretion of the treating physician in
consultation with the patient and was primarily dependent on the age and general health of
the patient as well as the perceived refractoriness of the disease. MAC regimens consisted
primarily of cyclophosphamide and total body irradiation (14 Gy in 7 fractions). RIC
regimens consisted of fludarabine 30 mg/m2 and intravenous busulfan 0.8 mg/kg, both given
for 4 days. Seven patients eligible to be included in the RIC cohort were enrolled on a
clinical trial of vaccination with killed autologous tumor after HSCT and were excluded
from the analyses. Comorbidity scores were determined by retrospective chart review(30).
Donors
All donors included in this analysis were HLA matched at A, B, and DR loci. Between 1998
and 2000, class I typing was low resolution, with high resolution class II typing for unrelated
donors. Between 2001 and 2004, allele level typing was added for HLA-A and HLA-B, with
high resolution class II typing. From 2005 to the present, high resolution molecular typing
has been used for HLA class I and II for all donors. HLA C mismatches were present in 9 of
the 90 patients tested; patients undergoing HSCT early in this time period were not
uniformly assessed for HLA C status. PBSC donors were mobilized with filgrastim at 10
mcg/kg/day for 5 days. Stem cell collection began on day 5 of filgrastim and was targeted to
collect >5 × 106 CD34+ cells/kg. Donor bone marrow was collected in the operating room
under anesthesia and the targeted cell dose was >2 × 108 nucleated cells/kg.
GVHD Prophylaxis
All patients received immunosuppressive therapy for GVHD prophylaxis on consecutive
protocols. The distribution of regimens is detailed in Table 1. No anti-thymocyte globulin or
alemtuzumab was used as part of HSCT conditioning, but 9 MAC patients did receive grafts
that underwent ex vivo T cell depletion. No planned or preemptive donor lymphocyte
infusions (DLIs) were given after RIC HSCT. Immunosuppressive medications were tapered
as clinically permitted over 3–12 months following HSCT. All patients received prophylaxis
for Pneumocystis jurivecii pneumonia and Herpes/Varicella virus reactivation. Patients were
monitored for peripheral blood CMV reactivation by DNA hybrid capture or quantitative
PCR assays during the first 100 days post transplant, and pre-emptive therapy with
ganciclovir or valganciclovir was started if CMV reactivation was detected. Acute and
chronic GVHD was graded according to consensus criteria(31, 32).
Cytogenetic Analysis
Standard metaphase karyotype analysis was performed on bone marrow aspirates or
peripheral blood, together with fluorescence in situ hybridization (FISH) for the most
common CLL abnormalities, as previously described(33). If FISH analysis was not
performed on a sample with active disease, patients were considered unevaluable for
cytogenetic abnormalities. Cytogenetic data were available for 12 patients undergoing MAC
HSCT and 51 patients undergoing RIC HSCT. The analyses of cytogenetics and outcome
were therefore confined to the patients undergoing RIC HSCT. Please see Supplementary
Methods for further details of this analysis.
Statistical Analysis
Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-
Meier method. OS was defined as the time from stem cell infusion to death from any cause;
those alive or lost to follow-up were censored at the date last known alive. PFS was defined
as the time from stem cell infusion to disease relapse, progression or death from any cause,
whichever occurred first. Complete and partial remission and progressive disease were
defined according to the National Cancer Institute Working Group (NCI-WG) criteria for
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CLL used at the time these transplantations were performed(34), supplemented with CT
scan evaluation and surveillance bone marrow biopsies with flow cytometry. Patients who
were alive without disease relapse or progression were censored at the time last seen alive
and disease-free. Please see Supplementary Methods for additional details on the statistical
approach.
RESULTS
Patient Characteristics and Outcomes for MAC and RIC Transplantations
The characteristics of this patient population are detailed in Table 1. In the entire study
period, the patient populations for MAC and RIC transplantations differed systematically
with respect to age, stem cell source, related vs. unrelated donor and use of sirolimus-
containing GVHD prophylaxis. For the entire population, PFS and OS were not significantly
different between the two conditioning groups (Table 3).
However, we noted that the risk of death in relation to year of transplantation declined
significantly beginning in 2004, suggesting that a significant OS difference would be evident
between HSCTs performed prior to 2004 compared to after (Supplementary Figure 1). We
therefore looked at HSCTs performed between 2004 and 2009. First, we noted that the MAC
and RIC patient populations were more comparable, with the only significant differences
being age (median age 47 vs 57, respectively, p=0.0001; Table 1) and the percentage of
patients who were purine analogue refractory (86% for MAC vs 48% for RIC, p=0.02, Table
1). A significant OS advantage favoring RIC HSCT did emerge for this later period (5-year
OS: 83% in RIC and 47% in MAC, p=0.003; Table 3, Figure 1A), with a suggestion of a
difference in PFS which did not reach statistical significance (64% in RIC and 47% in
MAC, p=0.15; Table 3, Figure 1B). As shown in Table 3, this difference in OS and PFS for
RIC HSCT was primarily due to lower NRM compared to MAC HSCT and improved
relapse rate compared to earlier time periods of RIC (5 year cumulative incidence of NRM
46% for MAC vs 9.5% for RIC, p=0.001; 5 year cumulative incidence of relapse 7% for
MAC vs 26% for RIC, p=0.13). In addition, the rate of grade II–IV acute GVHD was
significantly lower with RIC compared to MAC (31% vs 57%, respectively, p=0.02). These
outcomes justify the current focus on RIC HSCT in CLL, and we will therefore focus the
remainder of our discussion on that patient population.
RIC Patient Characteristics
Additional details of the 76 patients who underwent RIC HSCT between 2001 and 2009 are
provided in Table 2. The median number of prior regimens was 4, and 43% were
transplanted with stable or progressive disease (Table 1). 30% of patients had an elevated
LDH and 21% had bulky disease at the time of transplantation. 30% had known high risk
cytogenetics (complex, del17p, or del11q), with an additional 33% lacking cytogenetic data.
62% of patients had a comorbidity score of zero, but retrospective determination may have
underestimated the true comorbidity in some patients.
RIC Progression-Free and Overall Survival
With a median follow-up of 5.1 years in survivors, the 5 year OS was 63% (95% CI 51–
73%), and the 5 year PFS was 43% (31–55%) (Table 3, Figures 1A, B). For the period since
2004, with a median follow-up of 4.7 years, the 5 year OS was 83%. We were interested in
exploring predictors of outcome in these RIC HSCT patients. In evaluating age, we observed
that worse outcomes were seen at both lower and higher ages, with the lowest risk at about
age 55 (higher risk < 50, >=65; Supplementary Figure 2). This is likely because in the time
period when many of these transplantations were done, the patients under age 50 who
underwent RIC HSCT had specific contraindications to MAC HSCT, including prior HSCT
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(n=6), comorbidities (n=6) or very poor disease status (n=10). For the purposes of further
analysis we therefore dichotomized age as between 50 and 64 inclusive, or outside that
range. This variable defined a 5 year OS of 74% for those aged 50–64, as compared to 44%
for those outside that range (p=0.002, Supplementary Figure 3).
In univariable analysis assessing predictors of OS, age (HR 0.35 for age 50–<65 vs age>=65
or age<50, p=0.003), disease status at conditioning (HR 2.67 for SD/PD vs CR/PR,
p=0.005), sirolimus use (HR 0.28, p=0.0003), bulk (HR 2.21 for >5cm vs <=5cm, p=0.01),
LDH (HR 2.21 for high vs low, p=0.02), comorbidity score (HR 2.0 for >=1 vs 0, p=0.04),
bone marrow involvement (continuous HR 1.01, p=0.005), and year of HSCT (HR 0.26 for
>=2004 vs <2004, p=0.0005) were significantly associated with OS (Supplementary Table
1). In univariable analysis assessing predictors of PFS, the same factors were significant,
with the addition of lymphocyte count at transplant conditioning, which was also
significantly associated with PFS (HR 1.31 for log transformed lymphocyte count, p=0.002;
Supplementary Table 1).
To reduce the number of predictors in Cox models, penalized multivariable Cox
proportional hazards models were constructed to evaluate the impact of pretransplantation
variables on PFS and OS. Significant variables predicting OS were age (HR 0.35 for 50–
<65, p=0.007), sirolimus containing GVHD prophylaxis (HR 0.29, p=0.0005), bulk > 5 cm
(HR 4.17, p = 0.003), bone marrow involvement as a continuous variable (HR 1.01, p=0.03),
and year of transplantation (HR 0.37 for ≥2004 compared with <2004, p=0.01) (Table 4).
Disease status was not selected due largely to its collinearity with bulky disease. Significant
variables predicting PFS were age (HR 0.38 for 50–64, p=0.005), SD/PD compared to CR/
PR (HR 2.32, p=0.02), bone marrow involvement as a continuous variable (HR 1.01,
p=0.023), log-transformed lymphocyte count (HR 1.33, p=0.006), high LDH (HR 2.50,
p=0.01) and comorbidity score >=1 (HR 2.09, p=0.025; Table 4).
RIC Non-Relapse Mortality and Relapse
Infection, GVHD and respiratory failure were the most common causes of NRM. Non-
relapse death accounted for 19 out of 35 deaths after RIC HSCT, compared to all 18 deaths
after MAC HSCT. The 5 year cumulative incidence of NRM in RIC HSCT was 16% for the
entire study period, and 9.5% for the 2004–2009 period (Table 3), showing improvement
over this period (Supplementary Figure 4A).
Relapse with or without death occurred in 30 patients in the RIC group. The 5 year
cumulative incidence of relapse in RIC HSCT was 40% for the entire study period and 26%
for the period 2004–2009, again showing improvement (Supplementary Figure 4B).
Univariable competing risks models were performed to assess the impact of
pretransplantation variables on relapse and on NRM. Significant predictors of relapse
included SD/PD at conditioning (HR 3.82, p=0.0004), an elevated LDH at HSCT (HR 3.3,
p=0.001), the log-transformed lymphocyte count (HR 1.33, p=0.001), age (HR 0.487 for 50–
64, p=0.049), and year of HSCT >= 2004 (HR 0.401, p=0.016) (Table 5). No significant
predictors of NRM were identified (data not shown).
RIC Graft vs. Host Disease
A lower incidence of grade 2–4 acute GVHD was observed for RIC HSCT compared to
MAC for the entire period (50% for MAC vs 30% for RIC, p=0.01), as well as since 2004
(57% for MAC vs 31% for RIC, p=0.02). However, in the RIC HSCT group, neither the
cumulative incidence of grade 2–4 acute GVHD nor the incidence of chronic GVHD
differed between the entire study period and the period since 2004 (30% vs 31%,
respectively, for aGVHD; 62% vs 63%, respectively, for cGVHD) (Table 3). In a landmark
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analysis that excluded early deaths and relapses prior to day 100, patients without cGVHD
showed a higher cumulative relapse rate compared to those with cGVHD (5 year cumulative
relapse rate: 53% vs 19%, p<0.001) but no significant difference was observed in NRM
(11% vs 17%, respectively, p=0.46). The cumulative incidence of acute and chronic GVHD
are shown for RIC HSCT in Supplementary Figures 5A and 5B.
RIC: Hematopoietic Donor Chimerism
Of the 76 patients, 72 patients had day 30 post HSCT donor chimerism data available. The
median donor chimerism achieved on day +30 was 92% (range 0, 100); and 74% (53/72)
achieved ≥75% donor chimerism by day 30. The 5 year OS for patients with donor
chimerism ≥75% at day +30 was 68% (95% CI: 54%, 79%) compared to 53% (95% CI:
29%, 72%) for those with <75% donor chimerism (p=0.03). The 5 year PFS for patients
with donor chimerism ≥75% at day +30 was 53% (95% CI: 37%, 66%) compared to 16%
(95% CI: 4%, 35%) for those with <75% donor chimerism (p=0.0002). The 5 year
cumulative incidence of relapse for patients with donor chimerism ≥75% at day +30 was
32% (95% CI: 19%, 46%) compared to 74% (95% CI: 46%, 89%) for those with <75%
donor chimerism (p=0.0006). In univariable logistic regression analysis, disease status (CR/
PR OR=4.59, p=0.008), lower bone marrow involvement (OR 1.03, p=0.003), lower log
lymphocyte count (OR 5.41, p=0.0002), and bulk<=5cm (OR 5.70 p=0.006) were predictors
of day 30 chimerism>=75%.
RIC Cytogenetics
In univariable analysis looking at 5 year PFS and OS for 17p deletion vs not, and 11q
deletion vs not, no difference in OS or PFS was observed in either group (Supplementary
Table 2, Supplementary Figure 6A). Although the degree to which 11q deletion and
complex abnormalities are high risk remain controversial in CLL, we did consider the effect
of any high risk cytogenetics, defined here as 17p, 11q, or complex (Supplementary Table 2;
Supplementary Figure 6B). The 5 year OS was 60% for patients with high risk cytogenetics
and 71% for patients with standard risk cytogenetics (p=0.68), and the 5 year PFS was 43%
and 51%, respectively (p=0.33) (Supplementary Table 2). In our previous analysis with
shorter follow-up, high-risk cytogenetics was a significant adverse predictor of PFS in
univariable analysis(28), but this is no longer the case with prolonged follow-up, in which
some patients with high-risk cytogenetics demonstrate extended survival.
A recent report suggested that complex cytogenetics alone are an adverse prognostic factor
for CLL after HSCT(35). Only 10 RIC patients in our cohort were known to have complex
cytogenetics, and they showed a 5 year OS of 40% compared to 72% for all others (p=0.15)
and a 5 year PFS of 40% compared to 49% for all others (p=0.75). Although this 5 year OS
difference appeared large, we found that 4 of 10 patients with complex cytogenetics are still
alive with follow up time ranging from 4 to 9 years, and thus OS curves equalized after 5
years (Supplementary Figure 6C).
RIC: Prognostic Model for PFS
We were interested in developing a model that would be prognostic of RIC HSCT outcome
in the current era. We chose to focus on predictors of PFS identified here because PFS has
the most events and is unaffected by choice of salvage therapy. Four variables were
considered in building the prognostic score: disease status at conditioning (SD/PD vs CR/
PR), LDH (high vs normal), comorbidity (>=1 vs 0), and lymphocyte count (>1000/μL vs
<=1000/μL). Age was not considered since it is not CLL specific, and bone marrow
involvement was not considered due to missing data. One point was assigned for each
adverse variable, namely SD/PD, high LDH, one or more comorbidities, or lymphocyte
count >1,000/μL. Variable specific scores were then summed and risk group was assigned
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based on the overall score. Using this grouping, our model successfully stratified patients by
5-year PFS, which was 83% for Score 0, 63% for Score 1, 24% for Score 2, and 6% for
Score >= 3 (p<0.0001; Table 6, Figure 2A). We then evaluated the association between our
prognostic model score and OS and relapse. The 5-year OS was 91% for Score 0, 78% for
Score 1, 63% for Score 2, and 22% for Score >= 3 (p<0.0001; Table 6, Figure 2B). The 5-
year cumulative incidence of relapse was 17% for Score 0, 15% for Score 1, 61% for Score
2, and 72% for Score >= 3 (p=0.00002; Table 6, Figure 2C). We conclude that this
prognostic score is highly associated with outcome in our cohort and should therefore be
validated in other CLL HSCT cohorts.
DISCUSSION
The optimal timing of HSCT in the treatment of CLL remains controversial and has become
even more difficult with the advent of highly effective novel therapies including the kinase
inhibitors ibrutinib and GS1101. Due to its ongoing risks, HSCT is often delayed until
patients have been multiply treated and have refractory disease, although a recent
retrospective comparison study suggested that even in that context, HSCT had survival
benefit compared to conventional therapy(36). Given this typical delay, however, relapse
rates after HSCT have remained significant. In this report, we explored the role of dose
intensity in transplantation outcome through a retrospective analysis of all CLL patients who
underwent allogeneic HSCT from 6/6 or better HLA matched adult donors at the DFCI/
BWCC between 1998 and 2009. In the entire cohort, PFS and OS were not different
between RIC and MAC approaches. In part this finding may result from the use of RIC
HSCT primarily in heavily pretreated higher risk patients in the earlier years. As experience
was gained, RIC has been used in a general patient population, resulting in similar patient
characteristics between the two groups. Thus, since 2004, a notable difference in OS
between the two groups, with an improved but not statistically different PFS, has become
apparent. This improvement is due to decreases in both NRM and relapse in RIC patients,
with minimal change in NRM in MAC patients. These findings suggest that the higher NRM
of MAC conditioning remains prohibitive and our ability to select a group of patients likely
to survive and potentially benefit from MAC HSCT for CLL remains limited. This appears
true despite the fact that virtually all the MAC survivors were cured. Thus, RIC HSCT
remains the transplantation of choice in this patient population. From our dataset we have
developed a prognostic model to further risk stratify patients for RIC HSCT, with the lowest
risk group having an extremely favorable 83% PFS at 5 years. This simple prognostic score
is based on pre-transplantation characteristics and separates patients very effectively based
on outcomes, including PFS, OS and relapse.
Even in the entire patient population, the outcomes of this RIC approach are extremely
favorable, with 63% overall survival, and particularly so in the cohort since 2004, with 83%
overall survival at 5 years. In part these outcomes are due to the notable safety of this RIC
approach, particularly since 2004, when NRM at 5 year follow-up is 9.5%, significantly
lower than NRM reported previously by ourselves and many others(22, 25, 28, 37). Similar
improvements were not seen in the MAC subgroup even in the period since 2004. The RIC
patient population did change after 2004, with more patients in remission at HSCT (72% vs
56% earlier). These remissions were mostly partial rather than complete, however, and the
median number of prior therapies did not differ between the two periods (p=0.76). Our
analysis did not identify any significant predictors of NRM due in part to the small number
of NRM events. The use of sirolimus for GVHD prophylaxis became routine at DFCI since
2004 and may have contributed, as acute GVHD was decreased after RIC HSCT.
Recent studies have raised the possibility that RIC HSCT may be associated with a higher
relapse rate(29), but we did not observe that in our analysis. Thus RIC HSCT benefited not
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just from reduced NRM but also from a decline in relapse rate from 40% in the overall
group to 26% in the 2004–2009 population, similar to the low relapse rate in another recent
report(37). The favorable relapse rate may be related in part to the higher percentage of
patients in partial remission at HSCT, since persistent significant disease burden at HSCT
has been repeatedly associated with increased relapse(25, 26, 28). Despite this improvement,
however, relapse does remain the primary cause of treatment failure. New approaches are
required to address it, including the use of novel therapies like the kinase inhibitors ibrutinib
and GS1101, either to achieve deeper remission prior to HSCT or to help induce or maintain
remission after HSCT.
Until then, improved patient selection may enhance outcomes. The primary predictors of
relapse in this study were markers of ongoing disease at HSCT, specifically absence of
remission, elevated LDH and lymphocyte count. From these variables, we were able to
develop a prognostic score which successfully stratifies patients with very different
outcomes after RIC HSCT and which may allow us to better determine the timing of HSCT
in individual patients. Although strongly associated with outcome in our cohort, we
nonetheless anticipate validating this score in independent cohorts to ensure its broad
applicability.
Recent reports have suggested an adverse effect of complex cytogenetics on transplantation
outcome(35). Due to missing data the power for the analysis of cytogenetic effects was
limited. However, many patients in our cohort with complex cytogenetics, del17p, or del11q
are still alive many years after RIC, suggesting that RIC HSCT can certainly result in long-
term survival in these patient subgroups. Larger studies will be required to determine
whether the rate of long-term survival is truly comparable between these high risk subgroups
and lower risk subgroups.
In this study we saw no apparent effect of sirolimus-containing GVHD prophylaxis on
relapse, although we have previously observed a beneficial effect in all lymphoid
malignancies(38). The effects of sirolimus on both NRM and relapse in our study are
difficult to differentiate from the effects of transplantation year, because sirolimus is closely
associated with HSCT since 2004. For that reason we await the results of our ongoing
multicenter randomized trial to draw more definitive conclusions about the impact of
sirolimus.
The strength of our study is our long term follow-up of a relatively large cohort of HSCT
patients with heavily pretreated CLL. The major weakness of our study is the changing
patient population over time, as with any retrospective analysis. Significant systematic
differences between the MAC and RIC patients are impossible to avoid, and even the RIC
patient population has likely evolved in more recent years. Nonetheless, these limitations do
not negate the extremely favorable findings in our recent RIC HSCTs, now with five year
follow-up.
Our data suggest that recent changes in the approach to RIC HSCT, including employing
HSCT earlier in the disease course or when the disease is in better control through
conventional therapy, have resulted in significantly improved outcomes. The excellent long-
term OS that we observe, resulting from recent improvements in both NRM and relapse,
justifies the consideration of RIC HSCT earlier in the disease course of high-risk CLL.
Although CLL is perceived as an indolent disease, most patients who require therapy,
particularly those with high risk prognostic markers, will die of their disease, and median
survival after either BR or FCR as a third-line regimen on a clinical trial has been reported
to be 34 and 47 months, respectively(5, 6). With the recent encouraging results with
ibrutinib and GS1101, the decision about the timing of transplant has become even more
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difficult for patients and physicians. Currently, however, follow-up with these drugs is still
short, and the degree to which they may alter the natural history of standard CLL therapy is
unclear. These drugs may also ultimately be able to further improve transplant outcomes by
inducing better remissions prior to transplant or by reducing relapse after transplant.
Meanwhile, our results suggest that the safety of RIC HSCT is now such that it should be
considered earlier in the course of relapsed disease, when patients are healthier, deeper
remissions are achievable, and long-term outcomes are therefore likely to be similar to those
reported here.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Survival Outcomes
A. Overall survival by conditioning regimen type and year. B. Progression free survival by
conditioning regimen type and year.
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Figure 2. Prognostic Score
A. 5-year PFS based on prognostic score: 83% for Score 0, 63% for Score 1, 24% for Score
2, and 6% for Score >= 3 (p<0.0001). B. 5-year OS based on prognostic score: 91% for
Score 0, 78% for Score 1, 63% for Score 2, and 22% for Score >= 3 (p<0.0001). C. 5-year
cumulative incidence of relapse based on prognostic score: 17% for Score 0, 15% for Score
1, 61% for Score 2, and 72% for Score >= 3 (p=0.00002).
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Table 5
Univariable Competing Risks Model for Relapse: RIC Cohort (n=76)
HR 95% CI p-value
50<=Age<65 vs Age<50 or Age>=65 0.487 0.28 1 0.049
SD/PD vs CR/PR 3.82 1.83 7.98 0.0004
BM Involvement: Continuous 1.01 1 1.02 0.057
Log (Lymphocyte Count) 1.33 1.12 1.58 0.001
LDH: High vs Normal 3.3 1.61 6.76 0.001
Year of HSCT: >=2004 vs <2004 0.401 0.191 0.841 0.016
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Table 6
RIC: Clinical Outcomes by Risk Score
Risk Score N
5-yr OS 5-yr PFS 5-yr Relapse
% (95% CI) % (95% CI) % (95% CI)
0 14 91 (51, 99) 83 (45, 95) 17 (2,45)
1 25 78 (54, 90) 63 (38, 80) 15 (3, 35)
2 19 63 (38, 80) 24 (17, 46) 61 (32, 80)
>=3 18 22 (7, 43) 6 (0.4, 22) 72 (42, 88)
p-value <0.0001 <0.0001 0.00002
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